Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
87.37 CHF +0.82% Intraday chart for Novartis AG +2.66% +2.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NOVARTIS AG : Barclays gives a Sell rating ZD
NOVARTIS AG : Berenberg remains Neutral ZD
Swiss Equities Ends Central Bank Week in the Red; Galderma Shines on Debut MT
Novartis Eyes Sale of Listed Unit in India CI
NOVARTIS AG : Buy rating from Deutsche Bank ZD
Novartis Says EU Regulator Panel Recommends Marketing Authorization for Fabhalta to Treat Blood Disorder MT
Novartis’ Oral Monotherapy for Rare Blood Disorder Secures EU Panel’s Nod MT
Novartis: positive opinion from CHMP to market Fabhalta CF
Novartis Wins European Medicine Agency Panel's Positive Opinion for Rare Blood Disorder Drug MT
Novartis Fabhalta(R) (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) DJ
Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria CI
MorphoSys Gets US Antitrust Approval for Proposed Acquisition by Novartis MT
Novartis' EUR2.7 Billion Purchase of MorphoSys Secures US Antitrust Clearance MT
BioNTech Q4 Earnings, Revenue Fall; Sets 2024 Revenue Guidance -- Shares Drop Premarket MT
BioNTech Names New Chief Commercial Officer MT
CAC40: Paris and E-Stoxx50 close at record highs CF
Repeat & Correct : Pfizer to Raise Around $3.5 Billion From Haleon Shares Sale -- Update DJ
CAC40: in record territory, oil at year's high CF
Pfizer to Raise Around $4.27 Billion From Haleon Shares Sale -- Update DJ
CAC40: new rebound after BoJ and ZEW indexes CF
CAC 40: no major upheaval after BoJ meeting CF
US appeals court revives Regeneron's antitrust lawsuit against Novartis RE
US appeals court revives Regeneron's antitrust lawsuit against Novartis RE
Novartis Expands Its Biopharmaceutical Manufacturing Site in Singapore CI
Morphosys sees no obstacle on its way under the Novartis umbrella DP
Chart Novartis AG
More charts
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
97.01 USD
Average target price
108.4 USD
Spread / Average Target
+11.73%
Consensus
  1. Stock
  2. Equities
  3. Stock Novartis AG - Swiss Exchange
  4. News Novartis AG
  5. Zacks Lifts Price Target on Novartis, Maintains Neutral Recommendation